Acquisition Corp Shenandoah serves as Executive at Sigilon Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Acquisition Corp Shenandoah has executed 1 insider transactions totaling $25.6M, demonstrating a bullish approach to their equity position. Their most recent transaction on Aug 11, 2023 involved purchasing 1,718,493 shares valued at $25.6M.
| DATE | TICKER | VALUE | TYPE | SHARES | PRICE | 10b5-1 |
|---|---|---|---|---|---|---|
| Aug 11, 2023 | SGTX | $25.6M | Purchase | 1,718,493 | $14.92 | Discretionary |
Acquisition Corp Shenandoah currently holds 100 shares of Sigilon Therapeutics, Inc. (SGTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Acquisition Corp Shenandoah has been a net buyer of SGTX stock. They have purchased $25.6M and sold $0 worth of shares.
Acquisition Corp Shenandoah's most recent insider trade was on Aug 11, 2023, when they purchased 1,718,493 shares at $14.92 per share.
Get notified when new Form 4 filings are submitted